Anti-IgE antibodies, such as omalizumab, are monoclonal antibodies designed to specifically bind to immunoglobulin E (IgE), a key mediator in allergic and inflammatory responses. IgE plays a central role in type I hypersensitivity reactions by binding to high-affinity receptors (FcεRI) on mast cells and basophils, leading to the release of histamine and other pro-inflammatory mediators upon allergen exposure. Anti-IgE therapy works by binding to the circulating free IgE, preventing it from interacting with FcεRI receptors and thereby reducing allergic inflammation. This mechanism also leads to the downregulation of FcεRI expression on effector cells over time, further decreasing cell activation and sensitivity to allergens.
In research settings, anti-IgE antibodies serve as valuable tools for studying the immunopathogenesis of allergic diseases, asthma, and chronic urticaria, as well as exploring IgE’s role in immune regulation and other non-allergic conditions. They are used to dissect signaling pathways involved in IgE-mediated responses and to evaluate the impact of IgE suppression on immune cell populations and cytokine profiles. Clinically, anti-IgE therapy has been approved for treating moderate-to-severe allergic asthma, chronic spontaneous urticaria, and other IgE-mediated disorders that are unresponsive to standard treatments. Ongoing studies are investigating its broader potential in food allergies, atopic dermatitis, and even certain autoimmune diseases, highlighting the biomarker’s growing significance in both translational and precision medicine research.
This product is manufactured in USA by Eagle Biosciences.
| Size | 1 x 96 Well |
| Sensitivity | 0.4808 ng/mL |
| Dynamic Range | 12 – 450 ng/mL |
| Incubation Time | 3 hours |
| Sample Type | Serum, Plasma |
| Storage | 2-8°C |
| Alternative Names | Anti-immunoglobulin E antibody, IgE-neutralizing antibody, IgE-blocking antibody, anti-IgE monoclonal antibody, or IgE inhibitor. |